Arcus Biosciences Inc
Suletud
SektorTervishoid
24.06 -2.08
Ülevaade
Aktsiahinna muutus
24h
Min
23.98
Max
24.93
Sissetulek | 37M -91M |
|---|---|
Müük | 24M 41M |
Aktsiakasum | -0.72 |
Kasumimarginaal | -221.951 |
Töötajad | 601 |
EBITDA | 38M -85M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +56.97% upside |
Järgmine tulemuste avaldamine | 26. okt 2026 |
|---|
Turukapital | 257M 3.7B |
|---|---|
Eelmine avamishind | 26.14 |
Eelmine sulgemishind | 24.06 |
Arcus Biosciences Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Arcus Biosciences Inc Prognoos
Hinnasiht
By TipRanks
56.97% tõus
12 kuu keskmine prognoos
Keskmine 38.6 USD 56.97%
Kõrge 47 USD
Madal 23 USD
Põhineb 10 Wall Streeti analüütiku instrumendi Arcus Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.